Revolution Medicines’ KRAS drug doubles survival
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines reported that its KRAS inhibitor daraxonrasib more than doubled median overall survival in a second‑line pancreatic cancer trial, extending life by six months versus standard chemotherapy.
- NCI director pledged to maintain robust oncology funding, seeking to allay researchers’ fears after prior concerns about Trump‑era budget cuts.
- Trump administration saw a judge reject its national‑security justification in a Hawaii case, underscoring ongoing legal challenges that contrast with the optimistic trial results.
Why it matters: Pancreatic cancer patients gain a new therapy that adds six months of life, while Revolution Medicines secures a potential market boost; the NCI’s funding reassurance steadies research investment after Trump‑era uncertainty.
Ask SkimNews
